LB Pharmaceuticals Inc (LBRX) stock
Close on Nov 13, 2026Market cap $1.39BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.39B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.32
- Dividend yield
- –
- Free cash flow yield
- -10.37%
Fundamentals
- Net income
- -$141.20M
- EPS, diluted
- -$3.13
- Free cash flow
- -$143.82M
- Book value per share
- $12.63
- Diluted shares
- 33M
Trading
- Next earnings
- Mar 25, 2027 (estimated, after the close)
- Previous close
- $42.46
- Open
- $42.66
- Day's range
- $41.02 – $43.42
- Volume
- 330,169
- Average volume (20 days)
- 353,097
- Index membership
- Russell 2000 (since Dec 2025), Russell 3000 (since Feb 2026)
- 52-week range
- $14.40 – $50.16
- RSI (14 days)
- 57.0
- Volatility (1 year)
- 63.4%
- Relative volume
- 0.91×
On 2 of our idea lists: Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | LBRX | S&P 500 | Difference | LBRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +23.6% | -3.0% | +26.7 pts | ||
| 3 months | -2.8% | -2.8% | −0.1 pts | ||
| Year to date | +93.2% | +11.5% | +81.7 pts | ||
| 1 year | +188.7% | +13.5% | +175.2 pts |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Net income
EPS, diluted
Free cash flow
Press releases
Releases LB Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- Update
- News
About LB Pharmaceuticals
Pharmaceutical Preparations
LB Pharmaceuticals Inc. is a late-stage biopharmaceutical company focused on developing therapies for various neuropsychiatric disorders, including schizophrenia, bipolar depression, and major depressive disorder. The company’s core effort centers on its lead product candidate, LB-102, a methylated derivative of amisulpride designed as a benzamide antipsychotic drug. LB-102 addresses positive, negative, and cognitive symptoms across clinical evaluations, aiming to serve patients who suffer from persistent psychiatric and mood conditions.
Company profile, executives and historyLB Pharmaceuticals stock: common questions
What is LB Pharmaceuticals's stock price?
LBRX closed at $43.01 on Nov 13, 2026, up 1.30% on the day. Over the past 52 weeks it traded between $14.40 and $50.16.
What is LB Pharmaceuticals's market cap?
LB Pharmaceuticals was worth $1.39B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is LBRX's P/E ratio?
LB Pharmaceuticals lost money over fiscal 2025 (diluted EPS -$3.13), so it has no meaningful P/E ratio.
Does LB Pharmaceuticals pay a dividend?
No. LB Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does LB Pharmaceuticals report earnings next?
LB Pharmaceuticals is expected to report Q4 FY2026 results on Mar 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has LBRX stock performed over the past year?
Including dividends, LBRX returned +188.7% over the past year, against +13.5% for the S&P 500.
How many LBRX shares are sold short?
6M shares were sold short at the latest FINRA report, 23.07% of the float, or 18.0 days of average trading volume.
Who are LB Pharmaceuticals's competitors?
Companies most similar to LB Pharmaceuticals by business, industry and size include NERV, XENE, ALZN, ANRO, PBM.
See a number that looks wrong?